Clinical Trials
53 trialsNCT03899987 2026-05-05
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT02737046 2026-03-10
Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
University of Miami
Phase 2 Completed
NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT04379518 2026-01-13
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00539591 2025-12-23
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT06450145 2024-06-10
APL
Zhejiang Provincial People's Hospital
Phase NA Recruiting
NCT01545141 2023-10-27
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT04081389 2023-09-11
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT03599453 2023-07-18
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Completed
NCT00679289 2022-10-12
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 2 Completed
NCT03403634 2022-03-02
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
Phase 2 Completed
NCT00398450 2021-03-03
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
University of California, San Diego
Phase 1 Completed
NCT02339324 2021-02-24
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
University of Pittsburgh
Phase 1 Completed
NCT00577993 2020-11-16
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00505635 2020-09-24
Biochemotherapy With Temozolomide for Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00498979 2020-07-24
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Case Comprehensive Cancer Center
Phase 1 Completed
NCT02151448 2020-07-20
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
University of Pittsburgh
Phase 1/2 Completed
NCT02331706 2020-04-21
IFN-DLI for Relapsed Acute Leukemia After Allo-SCT
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed
NCT00004088 2019-07-02
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT01603212 2019-05-21
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01100528 2019-02-26
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00629200 2018-11-15
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01460875 2018-11-02
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT00038376 2018-10-29
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03435302 2018-02-19
HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Peking University Cancer Hospital & Institute
Phase 3 Unknown
NCT00311558 2018-01-26
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
The Cleveland Clinic
Phase 1 Terminated
NCT00262951 2017-12-28
Chemoradiation in Locally Advanced Pancreatic Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT02615574 2017-09-26
A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT01622933 2017-08-31
Multiple Antigen-Engineered DC Vaccine for Melanoma
University of Pittsburgh
Phase 1 Completed
NCT00006244 2017-07-12
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01409174 2017-05-31
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00059826 2016-12-07
Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00548847 2016-10-26
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Emory University
Phase 2 Completed
NCT01860742 2016-04-05
CASTOR
Jules Bordet Institute
Phase 3 Withdrawn
NCT00445523 2016-03-17
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00522249 2016-03-17
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
The Methodist Hospital Research Institute
Phase 1/2 Terminated
NCT00083551 2015-11-23
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
University of Arkansas
Phase 3 Completed
NCT00375661 2015-09-02
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Kyoto University Hospital
Phase 4 Completed
NCT00082719 2015-05-14
Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01743157 2013-08-29
BBI
California Pacific Medical Center Research Institute
Phase 1/2 Completed
NCT00293527 2013-05-23
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01782508 2013-02-04
A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT00970996 2013-01-03
BCAA
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01158534 2012-08-07
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01409187 2012-01-26
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00561912 2011-12-26
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01259934 2010-12-14
Nordic Adjuvant IFN Melanoma Trial
Karolinska Institutet
Phase 3 Completed
NCT00221702 2010-10-13
EADO
University Hospital, Bordeaux
Phase 3 Completed
NCT00176527 2009-12-11
Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00963664 2009-09-09
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
NeoPlas Innovation
Phase 2 Withdrawn